Ascletis Pharma Inc
HKEX:1672
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.78
1.96
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ascletis Pharma Inc
Revenue
Ascletis Pharma Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Ascletis Pharma Inc
HKEX:1672
|
Revenue
ÂĄ56.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
||
Beigene Ltd
HKEX:6160
|
Revenue
ÂĄ17.4B
|
CAGR 3-Years
102%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Revenue
ÂĄ4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
337%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
ÂĄ5.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Revenue
ÂĄ8.3B
|
CAGR 3-Years
37%
|
CAGR 5-Years
31%
|
CAGR 10-Years
27%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Revenue
ÂĄ36.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
31%
|
CAGR 10-Years
47%
|
Ascletis Pharma Inc
Glance View
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
See Also
What is Ascletis Pharma Inc's Revenue?
Revenue
56.6m
CNY
Based on the financial report for Dec 31, 2023, Ascletis Pharma Inc's Revenue amounts to 56.6m CNY.
What is Ascletis Pharma Inc's Revenue growth rate?
Revenue CAGR 5Y
-19%
Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Ascletis Pharma Inc have been 17% over the past three years , -19% over the past five years .